

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

In re: )  
 ) Chapter 11  
NVN Liquidation, Inc., *et al.*, )  
f/k/a NOVAN, INC.,<sup>1</sup> ) Case No. 23-10937 (LSS)  
 )  
Debtors. ) Jointly Administered  
 )  
\_\_\_\_\_ )

**NOTICE OF AGENDA FOR HEARING  
SCHEDULED FOR FEBRUARY 20, 2024, AT 3:30 P.M. (ET)**

**THERE ARE NO MATTERS GOING FORWARD.  
WITH THE PERMISSION OF THE COURT, THIS HEARING HAS BEEN CANCELLED.**

**ADJOURNED MATTER**

1. Motion of Debtors for Entry of an Order Pursuant to 11 U.S.C. §§ 105(a) and 554 and Federal Rule of Bankruptcy Procedure 6007 Authorizing the Abandonment of Certain Unsellable Products Subject to Certain Regulatory Obligations ([D.I. 533](#), filed 1/19/24).

Response Deadline: February 2, 2024, at 4:00 p.m. (ET); extended to February 13, 2024, at 4:00 p.m. (ET) for the United States Food and Drug Administration (the “FDA”) and extended to February 15, 2024, at 4:00 p.m. (ET) for Integrated Commercialization Solutions, Inc. (“ICS”).

Responses Received:

- a) Informal response received from ICS.
- b) Objection by the United States to the Debtors’ Motion to Abandon ([D.I. 587](#), filed 2/12/24).

---

<sup>1</sup> The Debtors in these chapter 11 cases, along with the last four digitals of the Debtors’ federal tax identification number (if applicable), are: NVN Liquidation, Inc., (f/k/a Novan, Inc.) (7682) and EPI Health, LLC (9118). The corporate headquarters and the mailing address for the Debtors is P.O. Box 64, Pittsboro, NC 27312.



Related Documents:

- a) Debtors' Reply in Support of the Motion of Debtors for Entry of an Order Pursuant to 11 U.S.C. §§ 105(a) and 554 and Federal Rule of Bankruptcy Procedure 6007 Authorizing the Abandonment of Certain Unsellable Products Subject to Certain Regulatory Obligations (to be filed).

Status: The Debtors have agreed to resolve the informal response from ICS with additional clarifying language that will be included in a proposed form of order. The Debtors have provided a proposal to the FDA in an effort to resolve the objection of the FDA. To give the FDA and other parties in interest time to consider the proposal, the Debtors and FDA have agreed to adjourn this matter to the omnibus hearing scheduled for March 6, 2024, at 10:00 a.m. If additional time is needed to reach an agreement, the Debtors may seek a further adjournment.

Dated: February 15, 2024  
Wilmington, Delaware

Respectfully submitted,

/s/ Casey B. Sawyer

**MORRIS, NICHOLS, ARSHT & TUNNELL LLP**

Derek C. Abbott (No. 3376)

Daniel B. Butz (No. 4227)

Tamara K. Mann (No. 5643)

Scott D. Jones (No. 6672)

Casey B. Sawyer (No. 7260)

1201 Market Street, 16th Floor

Wilmington, Delaware 19801

Telephone: (302) 658-9200

Facsimile: (302) 658-3989

Email: [dabbott@morrisnichols.com](mailto:dabbott@morrisnichols.com)

[dbutz@morrisnichols.com](mailto:dbutz@morrisnichols.com)

[tmann@morrisnichols.com](mailto:tmann@morrisnichols.com)

[sjones@morrisnichols.com](mailto:sjones@morrisnichols.com)

[csawyer@morrisnichols.com](mailto:csawyer@morrisnichols.com)

*Counsel to the Debtors and Debtors in Possession*